Massachusetts is the latest state going after insulin makers and the intermediaries officials accuse of price gouging. Why it ...
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...
UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended ...
In a report released today, Florent Cespedes from Bernstein maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth ...